azacitidine has been researched along with Leukemia, Myelomonocytic, Acute in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bech-Serra, JJ; Brooks, N; Buschbeck, M; Casquero, R; de la Torre, C; Diesch, J; Fellner, M; Gentilella, A; Götze, KS; Herráez, CM; Le Pannérer, MM; Maher, M; Muhar, M; Rathert, P; van der Garde, M; Winkler, R; Zamora, L; Zuber, J | 1 |
| Appelbaum, FR; Coutre, SE; Erba, HP; Godwin, JE; Howard, DS; Nand, S; Norwood, TH; Othus, M; Willman, CL | 1 |
| Hochhaus, A; Kunert, C; Schnetzke, U; Scholl, S; Schrenk, K; Spies-Weisshart, B | 1 |
| Du, Y; Ji, C; Ji, M; Li, P; Lu, F; Ma, D; Ye, J | 1 |
| Bernal, T; Gutiérrez-Fernández, A; Moncada-Pazos, A; Soria-Valles, C | 1 |
| Bekesi, G; Holland, JF; Richardson, EB; Silverman, LR; Zinzar, S | 1 |
| Fiere, D; Haanen, C; Jehn, U; Löwenberg, B; Peetermans, M; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Heinemann, V; Jehn, U | 1 |
3 trial(s) available for azacitidine and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Female; Gemtuzumab; Humans; Hydroxyurea; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Risk; Survival Analysis | 2013 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Belgium; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
5 other study(ies) available for azacitidine and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CREB-Binding Protein; DNA Methylation; Humans; Leukemia, Myelomonocytic, Acute; Protein Biosynthesis; RNA | 2021 |
Different clones of acute leukemia after successful treatment of Hodgkin's disease.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Bleomycin; Bone Marrow; Clone Cells; Consolidation Chemotherapy; Dacarbazine; Doxorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Palliative Care; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vinblastine | 2014 |
SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Bone Marrow; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Messenger; RNA, Neoplasm; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Young Adult | 2014 |
Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Catalysis; Cell Line, Tumor; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Induction; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms, Second Primary; Promoter Regions, Genetic; Risk | 2013 |
Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90.
Topics: Azacitidine; Cell Differentiation; Drug Synergism; Growth Substances; Humans; Immunophenotyping; Leukemia, Myelomonocytic, Acute; Recombinant Proteins; Verapamil | 1998 |